CELLINK welcomes new scientific advisor Professor Ido Amit from the Weizmann Institute of Science

Professor Ido Amit from the Immunology Department at the world-renowned Weizmann Institute of Science in Israel will be joining the CELLINK advisory board. Prof. Amit earned his PhD in biological regulation at the Weizmann Institute of Science in 2007. He was a postdoctoral fellow at the Broad Institute at Harvard University and the Massachusetts Institute of Technology for four years, before joining the Weizmann Institute in 2011.

Prof. Amit is a world leader and pioneer in development of single-cell genomic technologies and their application to characterize the immune system. Prof. Amit’s research addresses some of the most fundamental questions in immunology. His discoveries are enabling the development of new immunotherapy strategies for autoimmune disorders, neurodegenerative diseases, and cancer – which will lead to the next generation of immunotherapy treatments.

Prof. Amit is also known in the scientific community as a leader in the field of immunogenomics, which aims to detect and engineer genome sequences that are essential for the function of the immune system in normal physiology and disease. Among other awards, Prof. Amit is a recipient of the EMBO Gold Medal award and an HHMI International Research Scholar for his work revealing the function of the immune system.

The appointment of Prof. Amit to the scientific advisory board is part of CELLINK’s efforts to build a strong product portfolio for single-cell omics analysis. Coupling its innovative technologies for cell separation with its advances in pico- and nano-liter liquid handling, CELLINK seeks to develop automated workflows that will make single-cell omics analysis more accessible to laboratories around the world.

“We are truly looking forward to working with one of the most recognized experts in the single-cell analysis space,” said Dr. Julian Riba, Chief Scientific Officer at cytena, a CELLINK company with a focus on single-cell technologies. “Being an excellent immunologist, his in-depth knowledge of enabling technologies ranging from sample handling to biochemistry and bioinformatics will help us develop even better tools to tackle some of the most pressing questions in precision medicine.”

CELLINK’s advisory board will now have four advisors, including Rolf Claesson, who has served as Chairman of Bayer HealthCare and Tecan Group, as CEO of Bayer Diagnostics, and has held executive management positions within Pharmacia, including director of Hill-Rom and Supervisory Board member of Fresenius Medical Care; Dr. Ali Khademhosseini, who served as Professor at Harvard-MIT, Brigham and Women’s Hospital and at Harvard Medical School, was formerly Levi Knight Professor of Bioengineering, Chemical Engineering, and Radiology at UCLA, and has now been appointed Director and CEO of the Terasaki Institute for Biomedical Innovation; Prof. David Williams of Wake Forest School of Medicine, who is regarded as a leading authority on biomaterials, medical devices, and biocompatibility, and has authored and co-authored over 400 technical papers within his field of expertise.

For further information, please contact:

Erik Gatenholm, CEO                                                                                       Gusten Danielsson, CFO                             
Phone (Sweden): +46 73 267 00 00                                                                  Phone (Sweden): +46 70 991 86 04      
Phone (US): +1 (650) 515 5566                                                                        Phone (US): +1 (857) 332 2138
Email:
[email protected]                                                                                      Email: [email protected]                                

About CELLINK

CELLINK is a global life-science company providing technologies, products, and services to create, understand, and master cell and molecular biology, with a focus on three main application areas: bioprinting, analysis, and liquid handling & bioprocessing. The company develops and markets innovative cell culture technologies, enabling researchers in the life sciences to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016, CELLINK’s products have been adopted by researchers and scientists in more than 1,000 laboratories with more than 100 publication citations, the majority of the largest pharmaceutical companies and has been delivered to more than 55 countries around the world. The company’s vision is to create the future of medicine.

Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq Stockholm Main Market under CLNK B.

Senaste pressreleaserna
March 22, 2020RegulatoryUppdatering avseende COVID-19
November 18, 2019RegulatoryKallelse till årsstämma i CELLINK AB